N. K. Mamporia

N. K. Mamporia

Auto-generated profile, based on publicly available information

N. K. Mamporia

Central Clinical Hospital of St. Alexy of the Moscow Patriarchate

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2020 in Terapevticheskii arkhiv
Verified
Journal Article
Open access
PDF file
NSN. V. Sturov
N. V. Sturov
SPS. V. Popov
S. V. Popov
NMN. K. Mamporia
N. K. Mamporia
AMA. A. Mager
A. A. Mager
Selective inhibitors of sodium-glucose cotransporter belong to a new class of drugs for the treatment of type 2 diabetes mellitus. The mechanism of their action is based on insulin-independent reduction of glucose reabsorption in the proximal renal tubules, which leads to stimulation of its excretion in the urine and, accordingly, to a decrease in the concentration of glucose in the blood plasma. Drugs of this group demonstrate effectiveness in the treatment of type 2 diabetes, but their use may be associated with an increased frequency of urinary tract infections. Pharmacological glucosuria, which leads to a decrease in the concentration of glucose in the blood, creates the preconditions for the occurrence of urinary tract infections. Urinary tract and genital infections are the most common adverse events associated with the use of sodium-glucose cotransporter inhibitors. In the presented literature review for 20162019, the relationship between urinary tract infections in patients with type 2 diabetes mellitus and therapy with sodium-glucose cotransporter inhibitors was analyzed.